Study Evaluating the Tolerability of Bifeprunox in Healthy Subjects
- Registration Number
- NCT00581451
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Brief Summary
Safety and tolerability study in healthy volunteers
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 144
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description C bifeprunox bifeprunox 14 day D bifeprunox bifeprunox 9 day A bifeprunox bifeprunox 25 day B bifeprunox bifeprunox 14 day
- Primary Outcome Measures
Name Time Method Tolerability 28 days
- Secondary Outcome Measures
Name Time Method Safety 28 days
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of bifeprunox in modulating dopamine receptors in healthy subjects?
How does bifeprunox compare to other antipsychotic drugs in terms of tolerability and side effect profiles?
Are there specific biomarkers that correlate with improved tolerability of bifeprunox in phase 1 trials?
What adverse events were observed in the NCT00581451 trial and how were they managed in healthy volunteers?
What is the therapeutic potential of bifeprunox in psychiatric disorders beyond its phase 1 tolerability data?